Insider · CIK 0001698328
Timothy J. Sangiovanni
Files at ZVRA (ZEVRA THERAPEUTICS, INC.). First filing Feb 2, 2026, latest Feb 4, 2026.
In brief
Timothy J. Sangiovanni files SEC Form 4 as officer at ZVRA (ZEVRA THERAPEUTICS, INC.). Since Feb 2, 2026, Timothy J. Sangiovanni has reported 0 open-market buys worth $0 and 2 open-market sells worth $43k, the latest filed on Feb 4, 2026.
A track record needs three past buys with six months of prices behind them; Timothy J. Sangiovanni has 0, so none is measured yet.
The newest scored trade: sold $28k of ZVRA on Feb 3, 2026, filed Feb 4, 2026, scored 15 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 2 sells worth $43k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ZVRA: ZEVRA THERAPEUTICS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | ZEVRA THERAPEUTICS, INC. | $28k 3,000 shares | -9% | +40% from low-28% from high | |
| 0Weak | ZEVRA THERAPEUTICS, INC. | $15k 1,750 shares | -8% | +37% from low-30% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jan 30, 2026 | ZVRA ZEVRA THERAPEUTICS INC | 4,750 0.01% of outstanding | $42k | Jan 30, 2026 | none |
| Feb 13, 2025 | ZVRA ZEVRA THERAPEUTICS INC | 3,000 0.01% of outstanding | $23k | Feb 13, 2025 | none |
Transactions
Every row this insider has filed, 8 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 28, 2026 | ZVRA ZEVRA THERAPEUTICS, INC. | AGrant or award Stock Option (right to buy)derivative | +40,000 | $0.00 | $0 | 40,000 | May 29, 2026 |
| May 28, 2026 | ZVRA ZEVRA THERAPEUTICS, INC. | AGrant or award Restricted Stock Unitderivative | +20,000 | $0.00 | $0 | 20,000 | May 29, 2026 |
| Feb 3, 2026 | ZVRA ZEVRA THERAPEUTICS, INC. | SOpen-market sale Common Stock10b5-1 | -3,000 | $9.18 | $28k | 29,590 | Feb 4, 2026 |
| Jan 30, 2026 | ZVRA ZEVRA THERAPEUTICS, INC. | MOption exercise Common Stock10b5-1 | +6,333 | - | - | 22,674 | Feb 2, 2026 |
| Jan 30, 2026 | ZVRA ZEVRA THERAPEUTICS, INC. | SOpen-market sale Common Stock10b5-1 | -1,750 | $8.82 | $15k | 20,924 | Feb 2, 2026 |
| Jan 31, 2026 | ZVRA ZEVRA THERAPEUTICS, INC. | MOption exercise Common Stock10b5-1 | +11,666 | - | - | 32,590 | Feb 2, 2026 |
| Jan 30, 2026 | ZVRA ZEVRA THERAPEUTICS, INC. | MOption exercise Restricted Stock Unitderivative10b5-1 | -6,333 | $0.00 | $0 | 12,667 | Feb 2, 2026 |
| Jan 31, 2026 | ZVRA ZEVRA THERAPEUTICS, INC. | MOption exercise Restricted Stock Unitderivative10b5-1 | -11,666 | $0.00 | $0 | 11,668 | Feb 2, 2026 |
Questions about Timothy J. Sangiovanni
Answered from the filings on this page, as of the latest one.
Is Timothy J. Sangiovanni buying or selling?
In the last 12 months Timothy J. Sangiovanni reported 0 open-market buys worth $0 and 2 open-market sells worth $43k on SEC Form 4; the latest was sold $28k of ZVRA on Feb 3, 2026. Grants, option exercises and tax withholding are not counted.
How did Timothy J. Sangiovanni's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Timothy J. Sangiovanni has 0.
Where does Timothy J. Sangiovanni file Form 4?
Timothy J. Sangiovanni has filed Form 4 at ZVRA (ZEVRA THERAPEUTICS, INC.) as SVP, Finance & Corp Controller. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.